Abbott-Astellas Collaborate
Patients will be monitored for CMV viral load using Abbott Labs' RealTime CMV assay, which is performed on the Abbott m2000 System.
Patients will be monitored for CMV viral load using Abbott Labs' RealTime CMV assay, which is performed on the Abbott m2000 System.
Abbott announced today that it has signed an agreement to collaborate with Astellas Pharma Global Development in a Phase 3 clinical trial for ASP0113 (TransVax™), an investigational vaccine licensed from Vical Incorporated for preventing cytomegalovi…
NEW YORK, Sept. 5, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue: Global Medical Laboratories Industry http://www.reportlinker.com/p0960414/Global-Medical-Laboratories-Industry.html#ut…
NEW YORK, Sept. 4, 2012 /PRNewswire/ — Intercept Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic …
Among the companies with shares expected to actively trade in Tuesday's session are Campbell Soup, Medicis Pharmaceutical and Questcor Pharmaceuticals.
NEW YORK, Sept. 3, 2012 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue: Europe Orthopedic Devices Market Outlook to 2018 – Arthroscopy, Cranio …
Shares of Orchid Chemical advanced after the company agreed to sell Penem & Penicillin active pharmaceutical ingredients (APIs) business to Hospira for $200mn.
Sleep disorders are a large area. We are focused on one particular type of sleep disturbance called “non-restorative” sleep. People with this problem do sleep, but they don’t wake up feeling refreshed or feeling that their sleep has had the resto…
In this episode of Engineering Newswire — from Product Design & Development — the toilet gets redesigned; test flight of hypersonic Waverider fails; NASA's Morfius Project crashes and burns; MIT's autonomous planes flies indoors; sunglass…
Today’s stage from Golden to Boulder provided 102.8 opportunities for every rider not named van Garderen, to gain time on the race’s leader headed into the final day’s individual time trial.